Reviews/ACE Inhibitors and Angiotensin Receptor Blockers/ACE inhibitors: worse cardiovascular outcomes in Black patients
CV · ACEARB-CV-02 · v2
Borderline: within 4 points of the Likely/Uncertain boundary, so a re-grade could land either side.
One study built to answer this exact question looked at a large group of patients in routine care and found that Black patients given an ACE-inhibitor-based treatment had more combined heart problems than those not given it, while White patients did not show the same pattern [3]. Two analyses of a large trial back the general direction, showing an ACE inhibitor did worse than a water pill for stroke and other heart events, though those trials did not break their results out by race in the material reviewed [1][10]. A heart-failure analysis found the ACE inhibitor helped White patients avoid hospital stays but did not clearly help Black patients [17]. Against this, another large real-world study found that for cardiovascular death specifically, the ACE inhibitor actually did better than the alternative drug class in Black patients [7], so whether outcomes are worse depends on what the drug is compared with. The panel saw a consistent direction across several independent datasets but noted the one on-target study was observational with a result that barely reached significance, the trials were not race-split in this evidence, and the comparison drug matters, so it stopped short of treating the claim as settled.
A retrospective cohort of 434,646 patients (59,316 new ACE-inhibitor users, 47% Black) found a significant race-treatment interaction (p = 0.04) and poorer composite cardiovascular outcomes with ACE use in Black patients (8.69% vs 7.74%; p = 0.05) but not in White patients (6.40% vs 6.74%; p = 0.37), with higher Black-ACE rates of AMI, stroke and congestive heart failure [3]. ALLHAT showed lisinopril worse than chlorthalidone across the cohort for combined CVD (RR 1.10), stroke (RR 1.15) and heart failure (RR 1.19) [1], and its long-term follow-up showed a persistent excess of stroke mortality (AHR 1.19) and combined stroke (AHR 1.11) versus diuretic [10]. A pooled SOLVD analysis found enalapril cut heart-failure hospitalisation by 44 percent in White patients (P < 0.001) but not in Black patients (P = 0.74) [17]. A secondary analysis of ACCORD-BP and SPRINT found ARBs lowered the primary outcome relative to ACEi in non-Hispanic Black participants (P interaction 0.05) [9]. The contested point: The evidence divides on whether 'worse outcomes' is categorical or comparator-dependent: an ONTARGET-emulation cohort of 17,593 Black patients found ARBs associated with MORE cardiovascular deaths than ACEi in Black individuals (HR 1.20, 95% CI 1.02-1.40) [7], the opposite direction from [9]. It also divides on directness, because the only study that splits the result by race and targets the claim head-on [3] is observational with a borderline primary signal, while the ACE-inhibitor trials [1][10] are not race-stratified in this corpus.
All 26 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from ACE Inhibitors and Angiotensin Receptor Blockers, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only directly-on-claim result [3] is observational with a borderline primary signal (8.69% vs 7.74%, p=0.05) and a weak race-treatment interaction (p=0.04); residual confounding by indication is not excluded despite weighting.
Comparator-dependence: [7] shows ACEi associated with fewer CV deaths than ARB in Black individuals (HR 1.20 for ARB vs ACEi), so 'worse cardiovascular outcomes' is not categorical and depends on the unspecified comparator in the claim.
Where it remains uncertain. For cardiovascular death, ACE inhibitors were associated with FEWER events than ARBs in Black patients (HR 1.20 for ARB vs ACEi) [7], so whether ACE-inhibitor outcomes are 'worse' depends on the unspecified comparator in the claim.
Aleatory
The direct result in [3] sits on the significance threshold (8.69% vs 7.74%, p = 0.05; interaction p = 0.04), so random variation could plausibly move it either side of the line.
Epistemic
ALLHAT [1] and its follow-up [10] report the ACE-inhibitor penalty only for the whole cohort; the Black-specific hard-outcome split needed for this claim is absent from the corpus.
Inferential
[3] is observational; despite inverse-probability weighting, the authors' causal reading of the ACE-Black association is not insulated from residual confounding by why patients were prescribed an ACE inhibitor.
The load-bearing papers from a corpus of 26, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
ACEi monotherapy first-step inferior to diuretic for CVD/stroke/HF (whole cohort; Black subgroup not in text)
“For lisinopril vs chlorthalidone, lisinopril had higher 6-year rates of combined CVD (33.3% vs 30.9%; RR, 1.10; 95% CI, 1.05-1.16); stroke (6.3% vs 5.6%; RR, 1.15; 95% CI, 1.02-1.30); and HF (8.7% vs 7.7%; RR, 1.19; 95% CI, 1.07-1.31).”
Panel auditInternal validity: high · scope of inference: Hypertensive adults aged 55+ with a CHD risk factor, comparing first-step drug classes overall, not by race.Key limitations: no race subgroup in abstract · ACEi vs diuretic not vs no treatment
Direct, on-claim: ACEi associated with worse composite CV outcome specifically in Black patients
“These findings confirm clinical trial evidence that hypertensive blacks have poorer outcomes than whites when treated with an ACE inhibitor-based regimen.”
Panel auditInternal validity: medium · scope of inference: Hypertensive Black vs White new users of ACE inhibitors in a municipal health care system.Key limitations: observational confounding · ACE-based regimen not strict monotherapy · borderline p=0.05
ARB superior to ACEi for CV events in the Black subgroup, indirectly supporting ACEi relative inferiority
“ARBs were associated with a lower rate of the primary outcome among subgroups of male versus female participants, non-Hispanic Black versus non-Hispanic White participants, and those randomly assigned to standard versus intensive blood pressure ( P interaction: <0.01, 0.05, and <0.01, respectively).”
Panel auditInternal validity: medium · scope of inference: ACCORD-BP and SPRINT participants; new ARB vs ACEi users, Black subgroup.Key limitations: non-randomized drug exposure · comparator is ARB · borderline interaction p=0.05
Counter-signal: for CV death, ACEi is superior to ARB in Black patients — worse-outcome claim is comparator-dependent
“Compared to ACEi, ARB were associated with more events in Black individuals (HR 1.20 (95% CI: 1.02, 1.40); IRD% 1.07 (95% CI: 0.10, 2.04); number-needed-to-harm (NNH): 93)”
Panel auditInternal validity: high · scope of inference: UK routine-care Black, South Asian and White patients prescribed ARB or ACEi; comparative effectiveness of ARB vs ACEi.Key limitations: comparator is ARB not placebo or other classes · heterogeneity only for CV death not primary composite · observational emulation
4 of 26 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent directional support from independent datasets backs the claim, but observational borderline significance, comparator-dependence, and imperfect isolation of 'monotherapy' keep confidence in the Likely band.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Race-stratified hard-outcome data from ACE-inhibitor trials. The two trials carrying the claim [1][10] do not report their Black subgroups in this corpus, leaving the monotherapy effect in Black patients inferred rather than measured. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Prespecified race-subgroup analyses of ALLHAT and comparable first-step ACE-inhibitor-versus-diuretic trials reporting stroke, CVD and heart-failure endpoints for Black participants.
Open question: Does ACE-inhibitor monotherapy produce worse hard cardiovascular outcomes than a diuretic specifically in Black hypertensive patients? Why it is still open: ALLHAT and its follow-up [1][10] show the penalty only cohort-wide, and the one race-split study [3] is observational and borderline.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19